New Zealand Medicinal Cannabis Firms Propose Merger to Form Helius Health

LOS ANGELES- Three of New Zealand’s medicinal cannabis companies—Helius Therapeutics, Green Leaf Group, and Elysian Group—have announced plans to merge into a single entity named Helius Health. The proposed consolidation aims to integrate the full value chain of prescribing, manufacturing, and dispensing medicinal cannabis products. The merger is subject to shareholder approval, with finalization anticipated by the end of June.

Helius Therapeutics holds the distinction of being New Zealand’s first certified Good Manufacturing Practices (GMP) medicinal cannabis company. Green Leaf Group and Elysian Group operate specialist clinics, namely Cannabis Clinic and CannaPlus+, respectively. The integration of these entities is intended to address challenges such as industry fragmentation, limited access, and affordability issues that have affected the sector since the launch of the Medicinal Cannabis Scheme five years ago.

Guy Haddleton, Chairman of Helius Health, emphasized the merger’s goal to create a seamless, patient-centric ecosystem. He stated that the consolidation would enable the combined entity to reduce costs, expedite delivery, and enhance access to clinician-led care. Dr. Waseem Alzaher, Chief Executive of Cannabis Clinic, highlighted the merger’s potential to improve education for both the public and healthcare providers regarding available treatments.